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S erotonin (5-hydroxytryptamine [5-HT])plays an important role within the ner-
vous system (serotonergic neurons), en-
docrine system (enterochromaffin cells),
immune system (leucocytes), and many
other organ systems.1 The effects of seroto-
nin are mediated by a divergent group of
5-HT receptors, including several sub-
types.2 Research presented in this letter
involves genetic variants of the G-protein
coupled 5-HT2C receptor, linked to the
multifunctional phosphoinositide signal-
ling system primarily activating phospho-
kinase C.2 5-HT2C receptors are widely
distributed in the central nervous system
and have been implicated in processes
regulating mood, cognition, sleep, and ex-
trapyramidal control.3–5 The 5-HT2C receptor
gene (HTR2C) is chromosome X-linked and
contains various single nucleotide poly-
morphisms (SNPs), for example, rs6318,
which may be functional because it results
in the Cys23Ser amino acid substitution.6
This missense mutation has indeed been
associated with dysfunction of serotonergic
neurotransmission in various psychiatric
disorders, and in the development of ad-
verse effects of antipsychotic and antide-
pressant therapy, thus implicating functional
consequences.7–9 Recently, Fedorenko et al10
described a possible protective effect of the
23Ser-HTR2C in antipsychotic drug-induced
hyperprolactinemia. However, in another
patient population, an even higher associa-
tion was found between hyperprolactinemia
and the G-HTR2C allele of rs569959.11 The
5-HT2C receptor is an excitatory receptor
displaying constitutive activity in the ab-
sence of the neurotransmitter.12 Accord-
ingly, full blockade of the 5-HT2C receptor
decreases its excitatory activity and the acti-
vation of the affected cell. This mechanism
might also explain why atypical antipsy-
chotics have fewer propensities for Parkin-
sonism and tardive dyskinesia than classical
antipsychotic drugs.4 It could be argued that
the 23Ser-5HT2C variant will differently re-
spond to 5-HT2C antagonists, which might
also have consequences for the likelihood
of adverse reactions during treatment with
atypical antipsychotics. However, re-
combinant human 23Cys-5-HT2C and
23Ser-5-HT2C receptors did not differ
in their electrophysiological response
to 5-HT when expressed in Xenopus oo-
cytes.6 Also, experiments using COS-7
and HEK293 cell lines revealed no func-
tional difference between these variants.13
Okada et al,14 however, observed higher
constitutive activity of 23Ser-5-HT2C than
23Cys-5-HT2C receptors in Sf9 cell lines.
Recombinant receptors may not adequately
reflect the real life differences between genetic
variants because the differencesmaybe related
to epigenetic variability or the assessed SNP
may be in equilibrium with other genetic vari-
ants. Therefore, an ex vivo model to explore
the functionality of genuine human 23Cys-
5-HT2C and 23Ser-5-HT2C receptors in nor-
mal cells is urgently needed to explain the
effects of the Cys23Ser HTR2C missense
mutation or polymorphisms, which are not
in linkage disequilibrium with rs6318.
Serotonin also has an important role
as immune modulator.1 The effects may
be cell-specific and depend on the ex-
pression of serotonergic components in
immune cells.1 Similarities in 5-HT func-
tion within nerve and immune cells have
led to the suggestion that blood lympho-
cytes could be used as a convenient probe
for a number of neuronal cell functions.15
Marazziti et al16 demonstrated the presence
of specific messenger RNA for 5-HT2C re-
ceptors in resting lymphocytes of healthy
subjects and patients with obsessive-
compulsive disorder and with bipolar dis-
order. It is thus very well possible that
5-HT2C receptor's functionality can be
assessed by investigating the effects of
5-HT2C receptor agonists on intracellular
transduction. To this end, Zhang et al17 de-
veloped and optimized a cellular inositol
monophosphatase 1 assay for the character-
ization of 5-HT2C receptor ligands using
Chinese hamster ovary cells. Our aim was
to use a less complicated assay to determine
the functionality of 5-HT2C receptors in
readily available cells of human patients. We
have therefore investigated whether 5-HT2C
induced calcium uptake by lymphocytes
could be a viable alternative.
The aim of our study was to determine
whether intracellular calcium could be
measured upon stimulation of the 5-HT2C
receptor in human female peripheral mono-
nuclear cells (PBMCs). The methods and
obtained results are described in detail in
the supplemental material (Supplementary
Data, Supplemental Digital Content 1,
FIGURE 1. Effect of the calcium ionophore digitonin and the selective 5-HT2C agonistMK212on the calcium content of humanmonocytes. Freshly
isolated PBMCs of 2 female donors were incubated with increasing concentrations LPS (ie, 0 ng/mL, 1 ng/mL, 10 ng/mL, and 100 ng/mL LPS),
cultured overnight, and loaded with FluoForte dye. Figure (A) represents addition of 0.2 mM digitonin and (B) addition of 1 μMMK-212.
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http://links.lww.com/JCP/A508). In the first
trial, it was measured whether application
of a calcium ionophore (ie, digitonin) or di-
rect stimulation of the 5-HT2C receptor (ie,
MK-212, a selective 5-HT2C receptor ago-
nist) induced intracellular calcium increases
in freshly isolated PBMCs. A strong signal
was obtained after addition of the calcium
ionophore digitonin compared with control
samples. After the addition of ATP, a clear
[Ca2+] increase could be measured and also
histamine induced amodest increase in fluo-
rescence. However, neither α-methyl-5HT
nor MK-212 induced any difference com-
pared with control at any of the concentrations
tested. In the second series of experiments, the
freshly isolated PBMCs were incubated
overnight (17–22 hours), with increasing con-
centrations of lipopolysaccharide (LPS) (ie,
0 ng/mL, 1 ng/mL, 10 ng/mL, and 100 ng/mL).
This did not induce robust differences with
respect to the sensitivity to 5-HT2C receptor
stimulation (Fig. 1).
Hence, in human PBMCs, we failed to
showany effect of 5-HT2C receptor activation
on intracellular free calcium levels. Also,
LPS-induced monocyte activation failed to
affect the sensitivity for 5-HT2C receptor ago-
nists. This failure could be due to accidental in-
active 23Ser-5-HT2C receptor homozygosity
of the donors. However, because the
HTR2C gene is chromosome X-linked,
the frequency of the 23Ser allele in healthy
Caucasian males was only 0.139 and, be-
cause we used PBMCs of different female
donors, this is highly unlikely.
In our opinion, it is of the utmost im-
portance to study the activity of 5-HT2C re-
ceptors in normal humanCys23Ser HTR2C
(rs6318) carriers. It is important to note that
the amino acid substitution on position 23
of the 5-HT2C receptor is not necessarily
causing a change in activity. The SNP can
still be in equilibrium with other genetic
variants, and/or the different pharmacolog-
ical activity could be dependent upon the
proper biochemical (epigenetic) context
within human cells. Clearly, the latter can
only be elucidated using suitable material of
human carriers. Importantly, such a model
could be an important future tool for treat-
ment response prediction in psychiatry. Intra-
cellular calcium release of human PBMCs
may not be a viable model, so we urge our
colleagues to report their serendipitous find-
ings with other ex vivo models.
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